Why the study?
Does PEG 30-Fmoc-ANP prolong the blood pressure lowering effect compared to native ANP in Wistar rats?
Does PEG 30-Fmoc-ANP prolong the blood pressure lowering effect compared to native ANP in Wistar rats?
Reversible pegylation of atrial natriuretic peptide creates a prodrug that significantly prolongs its hypotensive effect in vivo, overcoming the short half-life of the native peptide.
No takes yet. Share an insight, caveat, or question.
Supports ANP prodrug development for sustained action; leaves open human translation from rodent data.
Nesher et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: